Harmony Biosciences Holdings, Inc. (HRMY) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 10 Buy, 1 Hold, 2 Sell.
The consensus price target is $46.80 (low: $31.00, high: $62.00), representing an upside of 59.8% from the current price $29.29.
Analysts estimate Earnings Per Share (EPS) of $2.36 and revenue of $0.71B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $2.56 vs est $2.36 (beat +8.7%). 2025: actual $2.76 vs est $3.20 (missed -13.8%). Analyst accuracy: 88%.
HRMY Stock — 12-Month Price Forecast
$46.80
▲ +59.78% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Harmony Biosciences Holdings, Inc., the average price target is $46.80, with a high forecast of $62.00, and a low forecast of $31.00.
The average price target represents a +59.78% change from the last price of $29.29.
Highest Price Target
$62.00
Average Price Target
$46.80
Lowest Price Target
$31.00
HRMY Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to Harmony Biosciences Holdings, Inc. in the past 3 months
EPS Estimates — HRMY
88%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $2.56
vs Est $2.36
▲ 8.0% off
2025
Actual $2.76
vs Est $3.20
▼ 16.0% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.
Revenue Estimates — HRMY
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.715B
vs Est $0.714B
▲ 0.0% off
2025
Actual $0.868B
vs Est $0.865B
▲ 0.4% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
